Clinical Trials Logo

Filter by:
NCT ID: NCT06294301 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

Start date: November 19, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-005 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-005 and Part 2, multiple ascending dose (MAD).

NCT ID: NCT06294288 Active, not recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).

NCT ID: NCT06294275 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome (MDS)

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

Start date: September 16, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-001 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-001 and Part 2, multiple ascending dose (MAD).

NCT ID: NCT06294184 Recruiting - Clinical trials for Transcranial Direct Current Stimulation

tDCS Interventions for Subthreshold Depressive Symptoms in Young Individuals.

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the mechanisms of the effect of transcranial direct current stimulation (tDCS) in alleviating subthreshold depressive symptoms in young individuals, and individualized outcome prediction is carried out.

NCT ID: NCT06293716 Not yet recruiting - Clinical trials for PI3K and P110delta Hyperactivation Syndrome

CVL237 Tablets for APDS/PASLI

Start date: March 30, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This study was designed to evaluate the efficacy and safety of CVL237 tablets in patients with APDS/PASLI (activated phosphoinositol 3-kinase δ syndrome /p110 delta-activated mutation leading to senescent T cells, lymphadenopathy, and immune deficiency).

NCT ID: NCT06293690 Not yet recruiting - Clinical trials for Non-small Lung Cancer

Toripalimab Combined With SBRT for NSCLC

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for operable or potentially operable stage IIa to IIIb NSCLC

NCT ID: NCT06293612 Completed - Clinical trials for Locally Advanced Rectal Cancer

Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer

MIS-MRC
Start date: January 1, 2015
Phase:
Study type: Observational

The goal of this observational study is to construct a multimodal intelligent model to predict the risk of heterochronous metastasis of rectal cancer, which is helpful for individualized diagnosis and treatment and follow-up planning. The main questions it aims to answer are: - what are the independent risk factors of distant metastasis (DM) in locally advanced rectal cancer (LARC) - What is the influence weight of the above factors on the heterochronous metastasis of LARC, and how to build a risk-prediction model This study will not affect or interfere with the routine medical diagnosis and treatment of participants, and will not increase the cost and risk of participants. Participant's information is protected and identified by a unique code.

NCT ID: NCT06293378 Recruiting - Cirrhosis, Liver Clinical Trials

Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This is a controlled, observational clinical study initiated by investigators to investigate the efficacy and safety of sulfasalazine in the treatment of cirrhosis in patients with cirrhosis. Four cohorts were planned: primary biliary cirrhosis, hepatitis B and C cirrhosis, and alcoholic cirrhosis. The four groups were divided into experimental group and control group, and the experimental group: each group of patients was orally treated sulfasalazine for 12 months, taken three times a day, each time taking 0.5g. The control group did not take sulfasalazine. After 12 months, changes in fecal flora and metabolites before and after the use of sulfasalazine were observed.

NCT ID: NCT06293287 Recruiting - Clinical trials for Radial Artery Occlusion

Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

The present investigation is designed as a single-blind, randomized, controlled, bicentric trial. The objective is to ascertain whether the subcutaneous administration of enoxaparin sodium for prophylactic anticoagulation during transradial hepatic arterial infusion chemotherapy (HAIC) can diminish the incidence of radial artery occlusion (RAO) post-procedure

NCT ID: NCT06293196 Recruiting - Clinical trials for Investigating the Effects of Periocular Acupressure on Ocular Biological Indicators

Effects of Acupoint Massage Around Eyes on Ocular Biological Indexes

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate whether the acupoint eye exercise could impact the biological parameters of the eye.